Cargando…

Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells

BACKGROUND: The effects of anti-inflammatory drugs in COPD patients may vary between different cell types. The aim of the current study was to assess the anti-inflammatory effects of the corticosteroid budesonide and a p38 MAPK inhibitor (AZD7624) on different cell types obtained from COPD patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higham, Andrew, Karur, Pradeep, Jackson, Natalie, Cunoosamy, Danen M, Jansson, Paul, Singh, Dave
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914546/ https://www.ncbi.nlm.nih.gov/pubmed/29719383 http://dx.doi.org/10.2147/COPD.S159936

Ejemplares similares

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
por: Patel, Naimish R, et al.
Publicado: (2018)

Dexamethasone and p38 MAPK inhibition of cytokine production from human lung fibroblasts
por: Higham, Andrew, et al.
Publicado: (2020)

Relationships between Airway Remodeling and Clinical Characteristics in COPD Patients
por: Higham, Andrew, et al.
Publicado: (2022)

Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages
por: Ratcliffe, Marianne Jennifer, et al.
Publicado: (2012)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Dysregulation of the CD163-Haptoglobin Axis in the Airways of COPD Patients
por: Higham, Andrew, et al.
Publicado: (2021)

The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation
por: Khan, Naimat, et al.
Publicado: (2018)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Identification of COPD Inflammatory Endotypes Using Repeated Sputum Eosinophil Counts
por: Beech, Augusta, et al.
Publicado: (2022)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Clinical impact of nasal budesonide treatment on COPD patients with coexistent rhinitis
por: Calabrese, Cecilia, et al.
Publicado: (2018)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD
por: Kurian, Nisha, et al.
Publicado: (2019)

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study
por: Portillo, Edward C., et al.
Publicado: (2023)

TIRAP-mediated activation of p38 MAPK in inflammatory signaling
por: Rajpoot, Sajjan, et al.
Publicado: (2022)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses
por: Higham, Andrew, et al.
Publicado: (2018)

Sensitization of colonic nociceptors by IL-13 is dependent on JAK and p38 MAPK activity
por: Barker, Katie H., et al.
Publicado: (2023)

Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
por: Barnes, Neil C, et al.
Publicado: (2021)

Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD
por: Bewley, Martin A., et al.
Publicado: (2016)

Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight
por: Higham, Andrew, et al.
Publicado: (2020)

Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV(1) in COPD patients
por: Huang, Cuiping, et al.
Publicado: (2013)

Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD
por: Khorasani, Nadia, et al.
Publicado: (2015)

Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
por: Um, Soo Jung, et al.
Publicado: (2013)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
por: Hanania, Nicola A., et al.
Publicado: (2020)

p38γ MAPK Inflammatory and Metabolic Signaling in Physiology and Disease
por: Qi, Xiao-Mei, et al.
Publicado: (2023)

Comparison of the Efficacy of Budesonide Nebulizer Suspension and Budesonide Inhalation Suspension in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Emami Ardestani, Mohammad, et al.
Publicado: (2018)

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD
por: Ji, Jie, et al.
Publicado: (2016)

Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate
por: Provost, Karin A., et al.
Publicado: (2019)

Effectivness of Nebulized Budesonide for COPD Exacerbation Management in Emergency Department; a Randomized Clinical Trial
por: Aghili, Mehrad, et al.
Publicado: (2020)

The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension
por: Church, Alistair C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2bp0dq79gimg65lqdeorc2imuh